News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alnylam Pharmaceuticals (ALNY) Forms Collaboration with Max Planck Institute of Molecular Cell Biology and Genetics Mechanisms for Cellular Uptake of RNAi Therapeutics


8/11/2008 8:24:17 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced it has formed an exclusive research agreement with the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, to investigate and characterize the molecular mechanisms underlying intracellular transport of small interfering RNA, (siRNA), the molecules that mediate RNAi.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES